Samareh Azeredo da Silveira Lajaunias
Dr. Azeredo da Silveira Lajaunias co-founded LASCCO SA in 2007 and built its portfolio focusing on discoveries in the fields of critical care and infectious diseases. From 2011 to 2019, she was a partner at Sepstone Diagnostics, a spin-off of LASCCO dedicated to the development of novel biomarkers for sepsis and overviewed the transfer of know-how and IP. Since 2015, she is General Manager at Combioxin SA and is responsible for the development CAL02, the company’s lead product. She validated models of acute infections (pneumonia / sepsis) for the assessment of a non-MIC agents to fight severe and resistant infections. She prepared and conducted meetings with regulatory authorities and managed the realization of the first-in-human trial in patients with CAL02 (Laterre PF et al. Lancet Infect Dis. 2019 Jun;19(6):620-630). Dr. Azeredo da Silveira Lajaunias holds a Ph.D. from the EPFL (Lausanne, Switzerland). She is the author of numerous publications and opinion reviews, and was rewarded as one of the 100 outstanding personalities contributing to the dynamism and innovation spirit in Switzerland (Forum des 100).